Form 4: Atossa Therapeutics Director Jonathan Finn Acquires 25,000 Shares

Director Jonathan Finn purchased 25,000 shares of Atossa Therapeutics at an average price of $1.77 on April 10, 2024.

Summary

• On April 10, 2024, Jonathan Finn, a director of Atossa Therapeutics, acquired 25,000 shares of common stock.
• The purchase was made at a weighted average price of $1.77 per share, with individual transactions ranging from $1.74 to $1.78.
• Following the transaction, Mr. Finn directly owns 25,000 shares of Atossa Therapeutics.
• The transaction was reported on Form 4, filed with the SEC on April 11, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a relatively small transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider trading activity is closely monitored as it can provide insights into a company's performance and future prospects. Purchases by insiders are generally viewed more favorably than sales.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates